Abstract
Researchers at Purdue and Endocyte have synthesized a series of radioimaging agents that could potentially detect prostate cancer masses and micrometastases that are beyond the detection limit of currently available imaging agents. One compound is expected to enter the clinic by the end of September.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
